Document Type : Meta-analysis
Authors
- Reza Noktehsanj 1
- Farzad Amouzadeh-Omrani 2
- Sayed-Mohammad-Amin Nourian 3
- Keyvan Amini 4
- Niloofar alsadat Nourian 5
1 Department of Surgery and Orthopedics, Ardabil University of Medical Sciences, Ardabil, Iran.
2 SBMU
3 California State University Stanislaus
4 Ardabil University of Medical Sciences
5 Islamic Azad University
Abstract
Background: Tanezumab is known as a new medical treatment for patients with osteoarthritis (OA) of the knee. We performed this meta-analysis to investigate the efficacy and safety of Tanezumab for treatment of patients with knee OA.
Methods: We systematically searched randomized controlled trials from MEDLINE, Scopus, EMBASE, EBSCO, and the Cochrane Central Register of Controlled Trials (CENTRAL). The selected primary outcomes for this study were mean change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain, the WOMAC physical function and patient's global assessment (PGA). Outcomes were reported using the standard mean difference (SMD) or odds ratio (OR) with 95% confidence interval (CI). We evaluated the pooled data using a random and fixed effects models.
Results: Of the studies that were found during systematic search, five studies were eligible and were included in this meta-analysis. Compared with the placebo groups, tanezumab showed a significant more reduction in mean of the WOMAC pain (SMD = -0.92, 95% CI -1.47 to -0.37, P=0.001), the WOMAC physical function (SMD = -0.59, 95% CI -0.79 to -0.39, P<0.01), and PGA (SMD = -0.36, 95% CI -0.45 to -0.27, P<0.01). There was no significant difference in serious adverse events (OR = 1.38, 95% CI 0.59 to 3.21, P = 0.48) between the tanezumab and placebo groups. Placebo significantly decreased discontinuations due to adverse events (OR = 0.37, 95% CI 0.21 to 0.64, P = 0.001), abnormal peripheral sensations (OR = 0.32, 95% CI 0.21 to 0.50, P<0.01), and peripheral neuropathy (OR = 0.25, 95% CI 0.13 to 0.48, P<0.01).
Conclusion: This meta-analysis showed that Tanezumab can decrease pain and improve function for patients with OA of the knee. However, due to the limited number of studies, this conclusion should be interpreted cautiously and further clinical randomized controlled trials will be required to approve the efficacy and safety of tanezumab for OA of the knee.
Keywords
- Dantas LO, Salvini TF, McAlindon TE. Knee osteoarthritis: key treatments and implications for physical therapy. Brazilian journal of physical therapy. 2020.
- Migliorini F, Driessen A, Oliva F, Maffulli GD, Tingart M, Maffulli N. Better outcomes and reduced failures for arthroplasty over osteotomy for advanced compartmental knee osteoarthritis in patients older than 50 years. Journal of orthopaedic surgery and research. 2020;15(1):545.
- Cross M, Smith E, Hoy D, Nolte S, Ackerman I, Fransen M, et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7):1323-30.
- Arden NK, Perry TA, Bannuru RR, Bruyère O, Cooper C, Haugen IK, et al. Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines. Nature reviews Rheumatology. 2020.
- Billesberger LM, Fisher KM, Qadri YJ, Boortz-Marx RL. Procedural Treatments for Knee Osteoarthritis: A Review of Current Injectable Therapies. Pain research & management. 2020;2020:3873098.
- Cao P, Li Y, Tang Y, Ding C, Hunter DJ. Pharmacotherapy for knee osteoarthritis: current and emerging therapies. Expert opinion on pharmacotherapy. 2020;21(7):797-809.
- Whelton A. Renal and related cardiovascular effects of conventional and COX-2-specific NSAIDs and non-NSAID analgesics. American journal of therapeutics. 2000;7(2):63-74.
- Watson JJ, Allen SJ, Dawbarn D. Targeting nerve growth factor in pain: what is the therapeutic potential? BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2008;22(6):349-59.
- Schnitzer TJ, Lane NE, Birbara C, Smith MD, Simpson SL, Brown MT. Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain. Osteoarthritis Cartilage. 2011;19(6):639-46.
- Hefti F. Pharmacology of nerve growth factor and discovery of tanezumab, an anti-nerve growth factor antibody and pain therapeutic. Pharmacological research. 2020;154:104240.
- Lane NE, Schnitzer TJ, Birbara CA, Mokhtarani M, Shelton DL, Smith MD, et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. The New England journal of medicine. 2010;363(16):1521-31.
- Schnitzer TJ, Marks JA. A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee. Osteoarthritis Cartilage. 2015;23 Suppl 1:S8-17.
- Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS medicine. 2009;6(7):e1000097.
- Ekman EF, Gimbel JS, Bello AE, Smith MD, Keller DS, Annis KM, et al. Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen. The Journal of rheumatology. 2014;41(11):2249-59.
- Nagashima H, Suzuki M, Araki S, Yamabe T, Muto C. Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study. Osteoarthritis Cartilage. 2011;19(12):1405-12.
- Brown MT, Murphy FT, Radin DM, Davignon I, Smith MD, West CR. Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial. The journal of pain : official journal of the American Pain Society. 2012;13(8):790-8.
- Amirfeyz R, Leslie I. AAOS (American Academy of Orthopaedic Surgeons) Clinical Practice Guideline. Treatment of carpal tunnel syndrome. Orthopaedics and Trauma. 2011;25(1):78.
- Bannuru RR, Schmid CH, Kent DM, Vaysbrot EE, Wong JB, McAlindon TE. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Annals of internal medicine. 2015;162(1):46-54.
- Bjordal JM, Ljunggren AE, Klovning A, Slørdal L. Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. BMJ (Clinical research ed). 2004;329(7478):1317.
- Webb MP, Helander EM, Menard BL, Urman RD, Kaye AD. Tanezumab: a selective humanized mAb for chronic lower back pain. Therapeutics and clinical risk management. 2018;14:361-7.
- Miller RE, Malfait AM, Block JA. Current status of nerve growth factor antibodies for the treatment of osteoarthritis pain. Clin Exp Rheumatol. 2017;35 Suppl 107(5):85-7.
- Seidel MF, Herguijuela M, Forkert R, Otten U. Nerve growth factor in rheumatic diseases. Seminars in arthritis and rheumatism. 2010;40(2):109-26.
- Miller RE, Block JA, Malfait AM. Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models? Current opinion in rheumatology. 2017;29(1):110-8.
- Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical research ed). 2008;336(7650):924-6.
- Zhang Z, Xu X, Ni H. Small studies may overestimate the effect sizes in critical care meta-analyses: a meta-epidemiological study. Critical care (London, England). 2013;17(1):R2.
)